Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment

Seamus Kent, Edward Burn, Dalia Dawoud, Pall Jonsson, Jens Torup Østby, Nigel Hughes, Peter Rijnbeek and Jacoline C. Bouvy ()
Additional contact information
Seamus Kent: National Institute for Health and Care Excellence
Edward Burn: University of Oxford
Dalia Dawoud: National Institute for Health and Care Excellence
Pall Jonsson: National Institute for Health and Care Excellence
Jens Torup Østby: Pfizer Inc
Nigel Hughes: Janssen Research and Development
Peter Rijnbeek: Erasmus University Medical Center
Jacoline C. Bouvy: National Institute for Health and Care Excellence

PharmacoEconomics, 2021, vol. 39, issue 3, No 2, 275-285

Abstract: Abstract There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these problems. The open-source Observational and Medical Outcomes Partnerships (OMOP) common data model standardises the structure, format, and terminologies of otherwise disparate datasets, enabling the execution of common analytical code across a federated data network in which only code and aggregate results are shared. While common data models are increasingly used in regulatory decision making, relatively little attention has been given to their use in health technology assessment (HTA). We show that the common data model has the potential to facilitate access to relevant data, enable multidatabase studies to enhance statistical power and transfer results across populations and settings to meet the needs of local HTA decision makers, and validate findings. The use of open-source and standardised analytics improves transparency and reduces coding errors, thereby increasing confidence in the results. Further engagement from the HTA community is required to inform the appropriate standards for mapping data to the common data model and to design tools that can support evidence generation and decision making.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00981-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:3:d:10.1007_s40273-020-00981-9

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00981-9

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().